We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > Resources > Industry Releases > Content Piece

Linneo Health and Phytocontrol Sign Exclusive Medicinal Cannabis Analysis Agreement

Published: Dec 14, 2022   
Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, and Phytocontrol, an international group of laboratories providing a complete range of analysis in agri-food, water, and biopharma, today announce that they have signed an exclusive clinical analysis collaboration agreement. The agreement gives Linneo Health access to Phytocontrol’s leading clinical analysis capabilities and allows both businesses to progress new developments and collaborations within the medicinal cannabis sector.

Linneo Health operates a state-of-the-art, good manufacturing practice (GMP) certified, quality control laboratory enabling the microbial and physical chemical analysis of its dried flower and cannabis extracts to ensure the highest pharmaceutical grade manufacturing standards are achieved. Through this collaboration, Linneo Health and Phytocontrol will exclusively develop enhanced methods for pesticide and active materials analyses that will further Linneo Health’s global reach and support entry into new medicinal cannabis markets, including Israel.

Regulations governing the research, cultivation, processing, and distribution of medicinal cannabis in Israel are some of the strictest in the world and the demonstration of Linneo Health’s product meeting these standards illustrates the Company’s commitment to quality. Israel’s medicinal cannabis market was estimated to be worth EU264 million in 20211, making it the second-largest medicinal cannabis market in the world outside of the US, and the largest medicinal market in the world per head of population.

This agreement has huge potential for both companies. It will allow Linneo Health to accelerate its growth and progress the development of new cannabinoid profiles or changes in the matrix, along with facilitating Phytocontrol’s first move into the medicinal cannabis sector, with the potential for future service collaborations between both companies.

Don Bellamy, Chief Executive Officer of Linneo Health, said: “As experts in our relative fields, this collaboration utilises both Linneo Health’s expertise in the medicinal cannabis sector and Phytocontrol’s leading clinical analysis capabilities. The work we will be doing with Phytocontrol will enable us to expand our reach, ensuring that we can meet the necessary requirements for entry into non-European markets, such as Israel. We’re excited about the potential of this collaboration and look forward to working closely with the Phytocontrol team going forward.”

Mikael Bresson, CEO of Phytocontrol, added: “We’re delighted to be collaborating with Linneo Health in a partnership that not only provides us with a port of entry into the Iberian market, but also marks our first venture into the medicinal cannabis sector. We share Linneo’s belief in the commitment to quality in everything we do, and we look forward to the mutual benefits that this collaboration will bring to both our organisations.”

This article has been republished from materials provided by Linneo Health. Note: material may have been edited for length and content. For further information, please contact the cited source.


Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter